RecruitingPhase 2NCT05983952

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Studying Antiphospholipid syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Lei Zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital
Intervention
Anti-CD38 antibody Injection(drug)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05983952 on ClinicalTrials.gov

Other trials for Antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Antiphospholipid syndrome →

← Back to all trials